Market Research Report
Schizophrenia - Pipeline Review, H2 2018
|Published by||Global Markets Direct||Product code||232781|
|Published||Content info||321 Pages
Delivery time: 1-2 business days
|Schizophrenia - Pipeline Review, H2 2018|
|Published: October 30, 2018||Content info: 321 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2018, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 13, 14, 18, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 1 molecules, respectively.
Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.